- Home
- NEO vs MDXG Comparison
NEO vs MDXG Comparison
Compare NEO & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEO
- MDXG
- Stock Information
- Founded
- NEO 2001
- MDXG 2006
- Country
- NEO United States
- MDXG United States
- Employees
- NEO N/A
- MDXG N/A
- Industry
- NEO Precision Instruments
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- NEO Health Care
- MDXG Health Care
- Exchange
- NEO Nasdaq
- MDXG Nasdaq
- Market Cap
- NEO 1.1B
- MDXG 1.0B
- IPO Year
- NEO 1999
- MDXG N/A
- Fundamental
- Price
- NEO $9.15
- MDXG $7.10
- Analyst Decision
- NEO Buy
- MDXG Buy
- Analyst Count
- NEO 10
- MDXG 1
- Target Price
- NEO $12.56
- MDXG $12.00
- AVG Volume (30 Days)
- NEO 3.0M
- MDXG 699.9K
- Earning Date
- NEO 10-28-2025
- MDXG 10-29-2025
- Dividend Yield
- NEO N/A
- MDXG N/A
- EPS Growth
- NEO N/A
- MDXG N/A
- EPS
- NEO N/A
- MDXG 0.21
- Revenue
- NEO $689,189,000.00
- MDXG $363,774,000.00
- Revenue This Year
- NEO $10.40
- MDXG $12.68
- Revenue Next Year
- NEO $10.11
- MDXG $8.18
- P/E Ratio
- NEO N/A
- MDXG $33.71
- Revenue Growth
- NEO 9.70
- MDXG 6.85
- 52 Week Low
- NEO $4.72
- MDXG $5.47
- 52 Week High
- NEO $19.12
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- NEO 67.00
- MDXG 55.89
- Support Level
- NEO $7.56
- MDXG $6.62
- Resistance Level
- NEO $9.24
- MDXG $7.35
- Average True Range (ATR)
- NEO 0.36
- MDXG 0.22
- MACD
- NEO 0.06
- MDXG 0.03
- Stochastic Oscillator
- NEO 92.86
- MDXG 83.49
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.